SEC Filing Summary: Supernus Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Supernus Pharmaceuticals, Inc. on December 7, 2015, covering events occurring on December 2, 2015, and December 4, 2015. The filing primarily addresses corporate events regarding investor relations and significant changes in shareholder ownership.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on non-financial corporate events.
Material Changes
- Investor Conference: Management announced plans to host investor meetings at the Guggenheim Securities 3rd Annual Boston Healthcare Conference on December 15, 2015.
- Shareholder Distribution: New Enterprise Associates (NEA) distributed an aggregate of 3,820,625 shares of Supernus common stock to its limited partners. Effective following the close of trading on December 3, 2015, NEA no longer holds any common stock in the Company.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the shareholder distribution event. The primary outlook provided is the scheduling of upcoming investor meetings.
Key Facts for Investor Verification
- Verify the impact of the 3,820,625 share distribution by New Enterprise Associates on the company's total outstanding share count and ownership structure.
- Confirm the date and agenda for the investor meetings at the Guggenheim Securities 3rd Annual Boston Healthcare Conference scheduled for December 15, 2015.
- Review the attached press releases (Exhibits 99.1 and 99.2) for additional details on the shareholder distribution and conference participation.